Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy. [PDF]
Liu Y, Guo J, Tang W, Xu G, Liu W.
europepmc +1 more source
Usage of brolucizumab as treatment for wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV): A narrative review. [PDF]
Jezani SN, Bastion MC.
europepmc +1 more source
Comparative outcomes of pars plana vitrectomy with subretinal rt-PA injection in polypoidal choroidal vasculopathy: the role of simultaneous anti-VEGF treatment. [PDF]
Chen L +5 more
europepmc +1 more source
Preferential Locations of Polypoidal Lesions and Adjacent Pigment Epithelium Detachments in Polypoidal Choroidal Vasculopathy in a Japanese Population. [PDF]
Kogo T +11 more
europepmc +1 more source
Correlation between complete polypoidal regression and visual outcomes in polypoidal choroidal vasculopathy eyes receiving intravitreal aflibercept. [PDF]
Chaikitmongkol V +10 more
europepmc +1 more source
Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined Subgroup Analysis. [PDF]
Cheung CMG +6 more
europepmc +1 more source
Comparative efficacy of photodynamic therapy (PDT), ranibizumab, aflibercept monotherapy, and combination therapies for polypoidal choroidal vasculopathy: a network meta-analysis of randomized controlled trials. [PDF]
Quiroz-Reyes MA +3 more
europepmc +1 more source
Clinical characteristics and long-term treatment outcomes of polypoidal choroidal vasculopathy with classic type leakage. [PDF]
Kim JH, Park SM, Kim JW, Kim CG.
europepmc +1 more source
Polypoidal Choroidal Vasculopathy Complicated by Red Blood Cell-Coated Intraocular Lens: A Case Report. [PDF]
Sawazono A +4 more
europepmc +1 more source

